LAVA Therapeutics NV’s recent filing unveils that its 10% Owner Cooperatieve Gilde Healthcare unloaded Company’s shares for reported $1.74 million on Oct 17 ’25. In the deal valued at $1.47 per share,1,181,131 shares were sold. As a result of this transaction, Cooperatieve Gilde Healthcare now holds 2,947,781 shares worth roughly $5.25 million.
Then, Cooperatieve Gilde Healthcare sold 690,239 shares, generating $1,028,456 in total proceeds. Upon selling the shares at $1.49, the 10% Owner now owns 4,128,912 shares.
Before that, Cooperatieve Gilde Healthcare sold 227,341 shares. LAVA Therapeutics NV shares valued at $343,285 were divested by the 10% Owner at a price of $1.51 per share. As a result of the transaction, Cooperatieve Gilde Healthcare now holds 5,019,151 shares, worth roughly $8.93 million.
Leerink Partners downgraded its LAVA Therapeutics NV [LVTX] rating to a Market perform from a an Outperform in a research note published on December 12, 2024; the price target was decreased to $2 from $11. A number of analysts have revised their coverage, including JMP Securities’s analysts, who decreased its forecast for the stock in mid December from “a Mkt outperform” to “a Mkt perform”. H.C. Wainwright began covering LVTX with “Buy” recommendation on October 25, 2022. SVB Leerink started covering the stock on April 19, 2021. It rated LVTX as “an Outperform”.
Price Performance Review of LVTX
On Tuesday, LAVA Therapeutics NV [NASDAQ:LVTX] saw its stock jump 7.23% to $1.78. Over the last five days, the stock has gained 10.56%. LAVA Therapeutics NV shares have risen nearly 7.23% since the year began. Nevertheless, the stocks have risen 87.17% over the past one year. While a 52-week high of $2.00 was reached on 11/18/25, a 52-week low of $0.85 was recorded on 02/12/25.
Levels Of Support And Resistance For LVTX Stock
The 24-hour chart illustrates a support level at 1.6650, which if violated will result in even more drops to 1.5500. On the upside, there is a resistance level at 1.8600. A further resistance level may holdings at 1.9400.
How much short interest is there in LAVA Therapeutics NV?
A steep rise in short interest was recorded in LAVA Therapeutics NV stocks on 2025-10-31, growing by 0.31 million shares to a total of 0.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 0.12 million shares. There was a rise of 72.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 19, 2021 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $22 price target.
